How to make your money go further
The Group’s proprietary chlorine dioxide formulation and the Company addresses three distinct markets:
- The Human Healthcare market (hospital infection prevention - via the Tristel brand) represents 85% of Group sales
- The Contamination Control market (control of contamination in critical environments - via the Crystel brand)
- The Animal Healthcare market (veterinary practice infection prevention - via the Anistel brand)
Tristel’s proprietary chlorine dioxide chemistry has two defining features: first, it kills bacterial spores very quickly; second, it is safe to use. As a consequence, Tristel’s surface disinfectants provide the most effective stratagem to control Clostridium difficile, one of the most problematic pathogens in hospitals.
For the year ending 30th June 2015 turnover was up 14% to £15.3m, pre-tax profit up 44% to £2.6m and basic earnings per share up a whopping 67% to 5.44p. The full year dividend per share was increased to 5.72p (2014: 1.62p) and included a special…
Register to continue reading this article.
Already a member? Login
For access to the top news and insights from the investment worldREGISTER FREE TODAY